


Cortellis 仿制药情报

查询美国专利挑战综述

了解如何在 Cortellis 仿制药情报数据库中，查看美国专利挑战综述信息。Cortellis 仿制药情报研究团队监控并收集美国专利挑战信息，每日更新内容。

例如：查询“rivaroxaban”（利戈沙班）的美国专利挑战综述

1. 使用“Quick Search”（快速检索）查看“rivaroxaban”（利戈沙班）药物报告



2. 在药物报告中，点击“US Patent Challenges”（美国专利挑战）模块。简化设计便于您打开表格，通过筛选标签查阅相关数据、专利诉讼、批准日期等。

Product Key Insights > US Patent Challenges

rivaroxaban

Product Key Insights API Manufacturers Regulatory Filings Approvals Launches & Pack Prices Constraint Date Forecast & Exclusivities Patents & SPCs **US Patent Challenges** Deals Competitive Insights R&D Scientific

XARELTO
NDA - 022406

Dose Form: Tablet Route: Oral Strength: 10MG 15MG 2.5MG 20MG

View Commentaries

US Patent Challenges

FILER	ASSOCIATED COMPANIES	APPLICATION NUMBER	STRENGTH	PATENTS LITIGATED	SUBMISSION/NOTIFICATION DATE	30 MONTH STAY	LITIGATION STATUS	APPROVAL DATE	LAUNCH DATE	COMMENTARY
Alembic Pharmaceuticals Ltd	No data	210301 (ANDA)	10mg, 15mg, 20mg	US-09539218	No data	No data	Closed	Filed	No data	By letter dated April 21, 2017, Bayer and Janssen received notice of Alembic's ANDA with Paragraph IV certification for a generic...
Aurobindo Pharma Ltd First to File: Assumed	No data	208544 (ANDA)	10mg, 15mg, 20mg	US-07157456 US-07585860 US-07592339 US-09539218	No data	No data	Closed	22-Jun-2018: Tentative	No data	By letter dated September 24, 2015, Bayer and Janssen received notice of Aurobindo's ANDA with Paragraph IV certification for a generic...

点击图标，展开图表

3. 点击“View Commentaries”（查看评论）按钮，打开可检索的美国专利挑战综述内容。

快速检索综述内容

导出 PDF

XARELTO NDA 022406

View Commentaries

Information about an ANDA with Paragraph IV certification for a generic version of Xarelto (rivaroxaban) tablets, 10mg, 15mg, and 20mg first appeared on the FDA website as of September 8, 2015. The FDA reports a submission date of July 1, 2015, which was the first day an ANDA could have been submitted for a rivaroxaban product. The New Chemical Entity exclusivity for rivaroxaban expired on July 1, 2016. The FDA reports eight ANDAs for generic versions of Xarelto tablets, 10mg, 15mg, and 20mg were filed on the first day possible and may share eligibility for the 180-day generic drug exclusivity.

Information about an ANDA with Paragraph IV certification for a generic version of Xarelto tablets, 2.5mg first appeared on the FDA website as of December 3, 2018. The FDA reports a submission date of November 19, 2018. According to the FDA, four ANDAs for generic versions of Xarelto tablets, 2.5mg were filed on the same day and may share eligibility for the 180-day generic drug exclusivity for that strength.

Alembic Pharmaceuticals Ltd: 210301 (ANDA)

^

By letter dated April 21, 2017, Bayer and **Janssen** received notice of Alembic's ANDA with Paragraph IV certification for a generic version of Xarelto tablets. On June 2, 2017, Bayer and **Janssen** filed a patent infringement suit against Alembic in the U.S. District Court for the District of Delaware in response to Alembic's ANDA. Bayer and **Janssen** alleged infringement of U.S. Patent 9,539,218. ¹ On November 13, 2017, the Delaware court consolidated the Alembic, Aurobindo, Breckenridge, InvaGen, Lupin, Micro Labs, Mylan, Sigmapharm, Taro, and Torrent cases concerning U.S. Patent 9,539,218. ² On June 15, 2018, the Delaware court stayed the case concerning U.S. Patent 9,539,218 with respect to Alembic and the parties agreed to be bound by any final judgment on the merits in the remaining consolidated action. ³ Trial in the consolidated case concerning U.S. Patent 9,539,218 began on April 5, 2019. ⁴ On March 2, 2020, the parties to the Lupin litigation stipulated to the dismissal of the matter with prejudice. ⁵ To our knowledge, no patent settlement terms have been disclosed. Alembic holds a DMF for rivaroxaban.

1: Bayer Intellectual Property GmbH et al. v. Alembic Pharmaceuticals Limited et al., U.S. District Court, D. Delaware, Case 1:17-cv-00675, 2017-06-02

2: Bayer Intellectual Property GmbH et al. v. Taro Pharmaceutical Industries Ltd. et al., U.S. District Court, D. Delaware, Case 1:17-cv-00462, 2017-11-13

3: Bayer Intellectual Property GmbH et al. v. Taro Pharmaceutical Industries Ltd. et al., U.S. District Court, D. Delaware, Case 1:17-cv-00462, 2018-06-15

4: Bayer Intellectual Property GmbH et al. v. Taro Pharmaceutical Industries Ltd. et al., U.S. District Court, D. Delaware, Case 1:17-cv-00462, 2019-04-05

5: Bayer Intellectual Property GmbH et al. v. Taro Pharmaceutical Industries Ltd. et al., U.S. District Court, D. Delaware, Case 1:17-cv-00462, 2020-03-02

欲了解更多信息，请与 **LS 产品支持** 客服联系